Skip to main content
Journal cover image

Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics

Publication ,  Conference
Hultcrantz, M; Anderson, LDJ; Anwer, F; Gasparetto, C; Kocoglu, MH; Lichtman, EI; Mo, C; Niesvizky, R; Lewis, E; Li, H; Paul, S; Petrone, S ...
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2021

Duke Scholars

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2021

Volume

21

Start / End Page

S439 / S440

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hultcrantz, M., Anderson, L. D. J., Anwer, F., Gasparetto, C., Kocoglu, M. H., Lichtman, E. I., … Kaufman, J. L. (2021). Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 21, pp. S439–S440).
Hultcrantz, Malin, Larry D Jr Anderson, Faiz Anwer, Cristina Gasparetto, Mehmet H. Kocoglu, Eben I. Lichtman, Clifton Mo, et al. “Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21:S439–40, 2021.
Hultcrantz M, Anderson LDJ, Anwer F, Gasparetto C, Kocoglu MH, Lichtman EI, et al. Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S439–40.
Hultcrantz M, Anderson LDJ, Anwer F, Gasparetto C, Kocoglu MH, Lichtman EI, Mo C, Niesvizky R, Lewis E, Li H, Paul S, Petrone S, Kaufman JL. Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S439–S440.
Journal cover image

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2021

Volume

21

Start / End Page

S439 / S440

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences